Request Free Sample ×
US Conjugate Vaccine Market — Global Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Conjugate Vaccine Market

ID: MRFR/Pharma/11305-CR
100 Pages
Satyendra Maurya
Last Updated: April 24, 2026

US Conjugate Vaccines Market Research Report: Size, Share, Trend Analysis By Types (Haemophilus B, Monovalent, Multivalent, And Others), Indication (Influenza, Pneumococcal, Meningococcal, And Others), End Users (Pediatrics And Adults)) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Conjugate Vaccine Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Chemicals and Materials, BY Type (USD Billion)
  49.     4.1.1 Meningococcal Conjugate Vaccines
  50.     4.1.2 Pneumococcal Conjugate Vaccines
  51.     4.1.3 Haemophilus Influenzae Type B Conjugate Vaccines
  52.     4.1.4 Typhoid Conjugate Vaccines
  53.   4.2 Chemicals and Materials, BY Indication (USD Billion)
  54.     4.2.1 Preventive Immunization
  55.     4.2.2 Therapeutic Use
  56.   4.3 Chemicals and Materials, BY Administration Route (USD Billion)
  57.     4.3.1 Intramuscular
  58.     4.3.2 Subcutaneous
  59.     4.3.3 Oral
  60.   4.4 Chemicals and Materials, BY End User (USD Billion)
  61.     4.4.1 Hospitals
  62.     4.4.2 Clinics
  63.     4.4.3 Pharmacies
  64.     4.4.4 Research Institutions
  65. 5 SECTION V: COMPETITIVE ANALYSIS
  66.   5.1 Competitive Landscape
  67.     5.1.1 Overview
  68.     5.1.2 Competitive Analysis
  69.     5.1.3 Market share Analysis
  70.     5.1.4 Major Growth Strategy in the Chemicals and Materials
  71.     5.1.5 Competitive Benchmarking
  72.     5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  73.     5.1.7 Key developments and growth strategies
  74.       5.1.7.1 New Product Launch/Service Deployment
  75.       5.1.7.2 Merger & Acquisitions
  76.       5.1.7.3 Joint Ventures
  77.     5.1.8 Major Players Financial Matrix
  78.       5.1.8.1 Sales and Operating Income
  79.       5.1.8.2 Major Players R&D Expenditure. 2023
  80.   5.2 Company Profiles
  81.     5.2.1 Pfizer (US)
  82.       5.2.1.1 Financial Overview
  83.       5.2.1.2 Products Offered
  84.       5.2.1.3 Key Developments
  85.       5.2.1.4 SWOT Analysis
  86.       5.2.1.5 Key Strategies
  87.     5.2.2 GlaxoSmithKline (GB)
  88.       5.2.2.1 Financial Overview
  89.       5.2.2.2 Products Offered
  90.       5.2.2.3 Key Developments
  91.       5.2.2.4 SWOT Analysis
  92.       5.2.2.5 Key Strategies
  93.     5.2.3 Merck & Co. (US)
  94.       5.2.3.1 Financial Overview
  95.       5.2.3.2 Products Offered
  96.       5.2.3.3 Key Developments
  97.       5.2.3.4 SWOT Analysis
  98.       5.2.3.5 Key Strategies
  99.     5.2.4 Sanofi (FR)
  100.       5.2.4.1 Financial Overview
  101.       5.2.4.2 Products Offered
  102.       5.2.4.3 Key Developments
  103.       5.2.4.4 SWOT Analysis
  104.       5.2.4.5 Key Strategies
  105.     5.2.5 Baxter International (US)
  106.       5.2.5.1 Financial Overview
  107.       5.2.5.2 Products Offered
  108.       5.2.5.3 Key Developments
  109.       5.2.5.4 SWOT Analysis
  110.       5.2.5.5 Key Strategies
  111.     5.2.6 Novartis (CH)
  112.       5.2.6.1 Financial Overview
  113.       5.2.6.2 Products Offered
  114.       5.2.6.3 Key Developments
  115.       5.2.6.4 SWOT Analysis
  116.       5.2.6.5 Key Strategies
  117.     5.2.7 AstraZeneca (GB)
  118.       5.2.7.1 Financial Overview
  119.       5.2.7.2 Products Offered
  120.       5.2.7.3 Key Developments
  121.       5.2.7.4 SWOT Analysis
  122.       5.2.7.5 Key Strategies
  123.     5.2.8 Boehringer Ingelheim (DE)
  124.       5.2.8.1 Financial Overview
  125.       5.2.8.2 Products Offered
  126.       5.2.8.3 Key Developments
  127.       5.2.8.4 SWOT Analysis
  128.       5.2.8.5 Key Strategies
  129.     5.2.9 Serum Institute of India (IN)
  130.       5.2.9.1 Financial Overview
  131.       5.2.9.2 Products Offered
  132.       5.2.9.3 Key Developments
  133.       5.2.9.4 SWOT Analysis
  134.       5.2.9.5 Key Strategies
  135.   5.3 Appendix
  136.     5.3.1 References
  137.     5.3.2 Related Reports
  138. 6 LIST OF FIGURES
  139.   6.1 MARKET SYNOPSIS
  140.   6.2 US MARKET ANALYSIS BY TYPE
  141.   6.3 US MARKET ANALYSIS BY INDICATION
  142.   6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
  143.   6.5 US MARKET ANALYSIS BY END USER
  144.   6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
  145.   6.7 RESEARCH PROCESS OF MRFR
  146.   6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
  147.   6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  148.   6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  149.   6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
  150.   6.12 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE)
  151.   6.13 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Billion)
  152.   6.14 CHEMICALS AND MATERIALS, BY INDICATION, 2024 (% SHARE)
  153.   6.15 CHEMICALS AND MATERIALS, BY INDICATION, 2024 TO 2035 (USD Billion)
  154.   6.16 CHEMICALS AND MATERIALS, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
  155.   6.17 CHEMICALS AND MATERIALS, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
  156.   6.18 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
  157.   6.19 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Billion)
  158.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  159. 7 LIST OF TABLES
  160.   7.1 LIST OF ASSUMPTIONS
  161.     7.1.1
  162.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  163.     7.2.1 BY TYPE, 2025-2035 (USD Billion)
  164.     7.2.2 BY INDICATION, 2025-2035 (USD Billion)
  165.     7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  166.     7.2.4 BY END USER, 2025-2035 (USD Billion)
  167.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  168.     7.3.1
  169.   7.4 ACQUISITION/PARTNERSHIP
  170.     7.4.1

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Type (USD Billion, 2025-2035)

  • Meningococcal Conjugate Vaccines
  • Pneumococcal Conjugate Vaccines
  • Haemophilus Influenzae Type B Conjugate Vaccines
  • Typhoid Conjugate Vaccines

Chemicals and Materials By Indication (USD Billion, 2025-2035)

  • Preventive Immunization
  • Therapeutic Use

Chemicals and Materials By Administration Route (USD Billion, 2025-2035)

  • Intramuscular
  • Subcutaneous
  • Oral

Chemicals and Materials By End User (USD Billion, 2025-2035)

  • Hospitals
  • Clinics
  • Pharmacies
  • Research Institutions

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓